GGrantIndex
Sort

8,912 grants matching sars cov 2

EAGER: Bioengineered Nanobarrier to Protect Against SARS-Cov-2 and Other Viral Infections of the Nasopharynx

$249,999
Isaac Asante · University Of Southern California · · FY2022 · ENG

First-in-class small molecules that enhance lung barrier function during acute respiratory distress syndrome (ARDS) as potential therapeutics for COVID-19

$249,998
Frederick M Ausubel · Artus Therapeutics Inc · R43 · FY2021 · HL

Manipulating nucleic acids: applications in RNA biosensing, single-molecule analysis, and DNA nanotechnology

$249,950
Ken A Halvorsen · State University Of New York At Albany · R35 · FY2023 · GM

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANT

$249,936
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2021 · CA

Prevention, Preparedness, and Response (P2R) Consortium: El Paso COVID-19 Recovery Training

$249,873
Janelle Rios · University Of Texas Hlth Sci Ctr Houston · U45 · FY2021 · ES

Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia

$249,863
Kristina Abel · Univ Of North Carolina Chapel Hill · R21 · FY2023 · AI

Development of the New Synthetic Triterpenoid CDDO-2P-Im for Chemoprevention of the ARDS of COVID-19

$249,799
Michael B Sporn · Triterpenoid Therapeutics, Inc. · R43 · FY2020 · CA

Metabolic Energy Crisis Signature Predicts Quality of Life in Survivors of Acute Respiratory Failure

$249,683
Raymond Julian Langley · University Of South Alabama · R21 · FY2021 · NR

Mechanisms of dysregulated immunity with aging

$249,600
Daniel Robert Goldstein · University Of Michigan At Ann Arbor · R01 · FY2020 · AG

Increasing representation of black communities in SARS-CoV-2 serosurveys by understanding barriers and motivations for participation

$249,582
Heather Bradley · Emory University · R01 · FY2023 · DA

Developing Lectins as Inhibitors of Coronavirus Spike Proteins

$249,000
Alex Joseph Guseman · University Of California, San Diego · R00 · FY2025 · GM

Theory and SImulation of Viral Replication

$249,000
Alvin Yu · University Of California-Irvine · R00 · FY2023 · AI

De novo design of a generalizable protein biosensor platform for point-of-care testing

$249,000
Hsien Wei Yeh · University Of California Santa Cruz · R00 · FY2023 · EB

CRISPR-based editing of RNA and cellular mechanisms that govern RNA repair

$249,000
Artem Aleksandrovich Nemudryi · University Of Florida · R00 · FY2024 · AI

Mechanisms of CRISPR-mediated immunity and applications beyond editing

$249,000
Andrew Santiago-Frangos · University Of Pennsylvania · R00 · FY2025 · GM

Targeted mRNA therapies treating ARDS

$249,000
Zhengjie Zhou · Temple Univ Of The Commonwealth · R00 · FY2025 · HL

Theory and SImulation of Viral Replication

$249,000
Alvin Yu · University Of California-Irvine · R00 · FY2024 · AI

De novo design of a generalizable protein biosensor platform for point-of-care testing

$249,000
Hsien Wei Yeh · University Of California Santa Cruz · R00 · FY2025 · EB

De novo design of a generalizable protein biosensor platform for point-of-care testing

$249,000
Hsien Wei Yeh · University Of California Santa Cruz · R00 · FY2024 · EB

Regulation of Pathologic Inflammasome Responses to SARS-CoV-2

$249,000
Katherine Camille Barnett · University Of Michigan At Ann Arbor · R00 · FY2025 · AI

Computational mapping of human B cell migration and differentiation pathways

$249,000
Kenneth Hoehn · Dartmouth College · R00 · FY2023 · AI

Neurobiological Mechanisms of Fatigue in Health and after COVID-19

$249,000
Agostina Casamento Moran · University Of Florida · R00 · FY2025 · NS

Mechanisms of CRISPR-mediated immunity and applications beyond editing

$249,000
Andrew Santiago-Frangos · University Of Pennsylvania · R00 · FY2024 · GM

Phylogenetic and computational methods for accurate and efficient analyses of large-scale metagenomics datasets

$249,000
Lenore Pipes · University Of Hawaii At Manoa · R00 · FY2025 · GM

Developing Lectins as Inhibitors of Coronavirus Spike Proteins

$249,000
Alex Joseph Guseman · University Of California, San Diego · R00 · FY2024 · GM